Correction: Landsbankinn hf.: Offering of covered bonds
Landsbankinn will offer covered bonds for sale via auction held on Wednesday 20 September at 15:00. A non-indexed series will be offered for sale, LBANK CB 27 in addition to a new non-indexed series, LBANK CB 29.
In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CB 23 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99.380.
Expected settlement date is 27 September 2023.
Covered bonds issued by Landsbankinn are rated A with positive outlook by S&P Global Ratings.
Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration3.10.2023 22:05:00 CEST | Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic ResearchCollaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human health Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages an
Kvika banki hf.: TM Insurance to be sold or listed3.10.2023 21:05:43 CEST | Press release
Following a strategic review at Kvika banki hf. ("Kvika" or "the bank"), the board of directors of Kvika has decided to initiate a process for the sale or listing of its insurance subsidiary TM tryggingar hf. ("TM"). The decision is in line with the bank's vision, where emphasis is placed on simplifying the group's operations and strengthening Kvika's traditional banking activities, in accordance with the bank's goal to increase competition and simplify its customers' finances. Following the divestment of TM, Kvika's main operations will be focused on commercial- and investment banking, along with asset management. It is expected that Kvika's capital base will grow significantly following the divestment of TM, enabling the bank to pursue internal growth opportunities across Kvika's business segments. Increased capital will, among other things, enable the bank to strengthen its market position, in both retail and corporate lending, and increase the risk diversification of its loan book.
Policane® Natural Sweetener Found to Have Low Glycemic Index3.10.2023 20:06:38 CEST | Press release
OCALA, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Policane®, a natural sweetener made from sugar cane juice in a patented process, has been found to have a low glycemic index (GI) in a study by IFP Suisse SA. According to the study Policane® has a GI of 51.7+/- 3.66. The study also found that Policane® had a 42% lower GI than white sugar. In its conclusion, the study recommends for Policane® a low glycaemic index product classification under International Standard ISO26642. “We are excited to share the results of this study, providing that Policane® is a low-GI sweetener,” said Jorge Enrique Gonzalez, Manager and CEO at PoliCane Co., LLC. “Policane® retains the best parts of the sugar cane stripped away in refined sugar. Policane® is a natural and sustainable sweetener that the world needs.” Policane® is currently produced under license in Costa Rica and can be used in recipes for all sweetened food and beverages, including baked goods, coffee, tea, colas, sauces, ketchup and desserts. Fo
Nokia Corporation: Repurchase of own shares on 03.10.20233.10.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 3 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 03.10.2023 Espoo, Finland – On 3 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL344,5423.53CEUX39,5413.54AQEU1,3923.53TQEX14,5253.55Total400,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Adevinta ASA – Procedures established in response to receipt of non-binding indicative proposal3.10.2023 19:30:00 CEST | Press release
Oslo, 3 October 2023 – Adevinta ASA (“Adevinta” or the “Company”) refers to the stock exchange announcement on 21 September 2023 regarding receipt of a non-binding indicative proposal (the “Proposal”) from a consortium led by Permira and Blackstone, with involvement of the Company’s two main shareholders, regarding a potential offer for all shares of the Company. In response to shareholder enquiries, the Company wants to communicate the procedures it is following in response to the Proposal. Immediately upon receipt of the Proposal, the Company’s board of directors established a special committee comprising the five independent directors on the Company’s board. The special committee is representing the Company in all aspects relating to the Proposal. The directors who are representatives of the three main shareholders of the Company are not involved in the Company’s deliberations and decisions. The independent committee is actively engaging in the Proposal in line with applicable regul